PCN64 CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN)
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)65222-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)65222-9/fulltext
Title :
PCN64 CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65222-9&doi=10.1016/S1098-3015(10)65222-9
First page :
Section Title :
Open access? :
No
Section Order :
381